Pfizer launches into autoimmune CAR T with China's Starna in up to $2.6B deal
The Chinese biotech will work with Pfizer on three in vivo CAR T therapies for autoimmune indications.
The Chinese biotech will work with Pfizer on three in vivo CAR T therapies for autoimmune indications.
comments(0)
5-min edit window · permanent after that